GE Global Research, a subsidiary of General Electric (GE), has partnered with Defense Advanced Research Projects Agency (DARPA) for a three-year research project valued at $2.9m.
The research project involves the development of new non-drug treatments for diabetes by using electronic medical devices. The devices will use technology, which stimulates metabolic biosystems to produce drug-like effects to treat diabetes.
Both GE Global Research and DARPA are research and development services firms based in the US.
The collaboration aims to develop a suitable alternative for treating diabetes with non-invasive medical devices, which causes less side effects compared to drug treatments.
Thermo Fisher Scientific has inked an agreement to acquire Becton, Dickinson and Company’s (BD) advanced bioprocessing business.
BD’s advanced bioprocessing business unit will be merged into Thermo Fisher’s Life Sciences Solutions Segment, as part of the agreement.
The transaction is expected to be closed in the first quarter of next year, subject to customary closing conditions.
Based in the US, Thermo Fisher is a medical devices developer, while BD, also based in the US, is a manufacturer of medical devices, instruments, and reagents.
The transaction will enable the acquirer company to expand its bio-production offering and increase its development and production capabilities.
Bio2 Technologies Inc has closed a series C equity financing round, which involved the participation of DSM Venturing, a private equity investment firm based in the Netherlands.
Based in the US, Bio2 Technologies is engaged in the development of advanced ortho-biomaterials.
The company plans to use the funds for conducting a clinical study for its spine product, Vitrium®, which is a novel resorbable ortho-biomaterial used in musculoskeletal surgery.
4C Medical Technologies (4C Medical) has raised $17m through the private placement of shares of its series A preferred stock.
Based in the US, 4C Medical is engaged in the development of minimally invasive therapies for structural heart diseases.
The company plans to use the funds raised to advance the development of its AltaValve™ Transcatheter Mitral Valve Replacement (TMVR) device, which allows replacement of mitral heart valves without the need for open-heart surgery.